mTORC2 signaling in metabolism and cell fate

NIH RePORTER · NIH · R01 · $38,726 · view on reporter.nih.gov ↗

Abstract

ABSTRACT Cell fate is influenced by the interplay of signals from the extracellular and intracellular environment. Studies over the years have revealed how the quality and quantity of signals triggered extracellular growth receptors mobilize intracellular signaling molecules leading to gene expression changes that dictate cell responses or fate. How such signals affect nutrient metabolism and how nutrient metabolites in turn control intracellular signaling, gene expression and ultimately cell fate remains poorly understood. A central signaling molecule that responds to nutrients and controls metabolism is mTOR. mTOR is an atypical Ser/Thr protein kinase that forms two protein complexes, mTORC1 and mTORC2. Numerous studies have focused on mTORC1, which is inhibited by the natural compound, rapamycin. mTORC1 is active in the presence of amino acids and promotes anabolic metabolism. In contrast to mTORC1, the regulation and functions of mTORC2 are poorly understood. In higher eukaryotes, mTORC2 is activated by growth factors such as insulin. Our project will elucidate how mTORC2 is involved in determining cell fate via its role in metabolic reprogramming during nutrient fluctuations. We will focus on how mTORC2 regulates the hexosamine biosynthetic pathway to control early thymocyte development. In this project, we will conduct quantitative proteomics to define alterations in metabolic and signaling pathways that occur when mTORC2 signaling or hexosamine pathway is modified. Our findings have implications for understanding how metabolism impacts cellular differentiation particularly in early T cell development. A deeper understanding of the regulation and functions of the mTOR complexes is needed for more effective therapeutic strategies against metabolic aberrations that occur during aging and diseases such as autoimmunity, diabetes and cancer.

Key facts

NIH application ID
10609270
Project number
3R01GM137493-03S1
Recipient
RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL
Principal Investigator
Estela Jacinto
Activity code
R01
Funding institute
NIH
Fiscal year
2022
Award amount
$38,726
Award type
3
Project period
2020-04-01 → 2023-03-31